Immunotherapy and enhanced antibody-dependent cell-mediated cytotoxicity using virally-infected target cells.
We examined the ability of in vitro addition of Interleukin-2 (IL-2) to differentially enhance antibody-dependent cell mediated cytotoxicity (ADCC) utilizing cultured Epstein-Barr virus infected cells and gammaglobulin (Sandoglobulin). We found significant enhancement of ADCC when IL-2 was added. Chronic Epstein-Barr virus or Chronic Fatigue Syndrome patients in a therapeutic gammaglobulin program may benefit from IL-2 given in vivo.
Bosse
D
D
Biological Products Branch, Centers for Disease Control, Atlanta, GA 30333.
Ades
E W
EW
D000920:Antibody-Dependent Cell Cytotoxicity / Q000187:drug effects / Q000276:immunology*; D002461:Cell Line, Transformed; D002472:Cell Transformation, Viral; D004854:Herpesvirus 4, Human / Q000276:immunology*; D006801:Humans; D007074:Immunoglobulin G / Q000494:pharmacology*; D016756:Immunoglobulins, Intravenous; D007376:Interleukin-2 / Q000494:pharmacology*
D007074:Immunoglobulin G; D016756:Immunoglobulins, Intravenous; D007376:Interleukin-2